Skip to main content
SpringerLink
Log in
Book cover

Imaging in CNS Drug Discovery and Development pp 215–228Cite as

Translational MRI in CNS Drug Discovery

  • Chapter
  • First Online:

  • 642 Accesses

Abstract

Translational neuroimaging has the potential to create a more successful link between preclinical and clinical research, thereby improving the predictivity of animal models and the development of innovative therapeutics. In this review, the emphasis is on “back translation”: how can clinical imaging data be best utilized to enhance preclinical drug discovery programs? Examples selected in the fields of Alzheimer’s disease and Schizophrenia elucidate the great potential – as well as some pitfalls – of translational MRI in CNS drug discovery.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  • Anand A, Charney DS, Oren DA et al (2000) Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Arch Gen Psychiatry 57(3):270–276

    Article  PubMed  CAS  Google Scholar 

  • Bartlett S (2005) MRI for in vivo detection of amyloid plaques. Lancet Neurol 4(5):276

    Article  PubMed  Google Scholar 

  • Beckmann N, Schuler A, Mueggler T et al (2003) Age-dependent cerebrovascular abnormalities and blood flow disturbances in APP23 mice modeling Alzheimer’s disease. J Neurosci 23(24):8453–8459

    PubMed  CAS  Google Scholar 

  • Benveniste H, Einstein G, Kim KR et al (1999) Detection of neuritic plaques in Alzheimer’s disease by magnetic resonance microscopy. Proc Natl Acad Sci USA 96(24):14079–14084

    Article  PubMed  CAS  Google Scholar 

  • Bertolino A, Callicott JH, Mattay VS et al (2001) The effect of treatment with antipsychotic drugs on brain N-acetylaspartate measures in patients with schizophrenia. Biological Psychiatry 49:39–46

    Article  PubMed  CAS  Google Scholar 

  • Bertolino A, Roffman JL, Lipska BK et al (2002) Reduced N-acetylaspartate in prefrontal cortex of adult rats with neonatal hippocampal damage. Cereb Cortex 12(9):983–990

    Article  PubMed  Google Scholar 

  • Bockhorst KH, Narayana PA, Liu R et al (2008) Early postnatal development of rat brain: in vivo diffusion tensor imaging. J Neurosci Res 86(7):1520–1528

    Article  PubMed  CAS  Google Scholar 

  • Braakman N, Matysik J, van Duinen SG et al (2006) Longitudinal assessment of Alzheimer’s beta-amyloid plaque development in transgenic mice monitored by in vivo magnetic resonance microimaging. J Magn Reson Imaging 24(3):530–536

    Article  PubMed  Google Scholar 

  • Brambilla P, Tansella M (2007) The role of white matter for the pathophysiology of schizophrenia. Int Rev Psychiatry 19(4):459–468

    Article  PubMed  Google Scholar 

  • Braus DF, Ende G, Weber-Fahr W et al (2001) Favorable effect on neuronal viability in the anterior cingulated gyrus due to long-term treatment with atypical antipsychotics: an MRSI study. Pharmacopsychiatry 34(6):251–253

    PubMed  CAS  Google Scholar 

  • Braus DF, Brassen S (2005) Functional magnetic resonance imaging and antipsychotics. Overview and own data. Radiologe 45(2):178–185

    Article  PubMed  CAS  Google Scholar 

  • Bustillo JR, Lauriello J, Rowland LM et al (2001) Effects of chronic haloperidol and clozapine treatments on frontal and caudate neurochemistry in schizophrenia. Psychiatry Research 107:135–149

    Article  PubMed  CAS  Google Scholar 

  • Bustillo JR, Rowland LM, Jung R et al (2007) Proton magnetic resonance spectroscopy during initial treatment with antipsychotic medication in schizophrenia. Neuropsychopharmacology 33(10):2456–2466

    Article  PubMed  Google Scholar 

  • Callicott JH, Bertolino A, Egan MF et al (2000) Selective relationship between prefrontal N-acetylaspartate measures and negative symptoms in schizophrenia. American Journal of Psychiatry 157:1646–1651

    Article  PubMed  CAS  Google Scholar 

  • Chan D, Janssen J, Fox NC et al (2003) Change in rates of cerebral atrophy over time in early-onset Alzheimer’s disease: longitudinal MRI study. Lancet 362(9390):1121–1122

    Article  PubMed  Google Scholar 

  • Deakin JF, Lees J, McKie S et al (2008) Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study. Arch Gen Psychiatry 65(2):154–164

    Article  PubMed  Google Scholar 

  • DeCarli C, Frisoni GB, Clark CM et al (2007) Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia. Arch Neurol 64:108–115

    Article  PubMed  Google Scholar 

  • Dedeoglu A, Choi JK, Cormier K et al (2004) Magnetic resonance spectroscopic analysis of Alzheimer’s disease mouse brain that express mutant human APP shows altered neurochemical profile. Brain Res 1012(1–2):60–65

    Article  PubMed  CAS  Google Scholar 

  • Definition ‘Translational Medicine’ in the internet encyclopedia Wikipedia. Accessed 26 May 2008 http://en.wikipedia.org/wiki/Translational_medicine

  • Ende G, Braus DF, Walter S et al (2000) Effects of age, medication, and illness duration on the N-acetyl aspartate signal of the anterior cingulate region in schizophrenia. Schizophr Res 41(3):389–395

    Article  PubMed  CAS  Google Scholar 

  • Ertugrul A, Uluğ B (2007) The effect of clozapine on neuroimaging findings in schizophrenia. Psychiatr Danub 19(4):367–369

    PubMed  Google Scholar 

  • Ezekiel F, Chao L, Kornak J et al (2004) Comparisons between global and focal brain atrophy rates in normal aging and Alzheimer disease: boundary shift integral versus tracing of the entorhinal cortex and hippocampus. Alzheimer Dis Assoc Disord 18(4):196–201

    PubMed  Google Scholar 

  • Fox NC, Freeborough PA (1997) Brain atrophy progression measured from registered serial MRI: validation and application to Alzheimer’s disease. J Magn Reson Imaging 7:1069–1075

    Article  PubMed  CAS  Google Scholar 

  • Fox NC, Cousens S, Scahill R et al (2000) Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects. Arch Neurol 57(3):339–344

    Article  PubMed  CAS  Google Scholar 

  • Fox NC, Schott J (2004) Imaging cerebral atrophy: normal ageing to Alzheimer’s disease. Lancet 363(9406):392–394

    Article  PubMed  Google Scholar 

  • Gozzi A, Large CH, Schwarz A et al (2008) Differential Effects of Antipsychotic and Glutamatergic Agents on the phMRI Response to Phencyclidine. Neuropsychopharmacology 33(7):1690–1703

    Article  PubMed  CAS  Google Scholar 

  • Grundman M, Petersen RC, Ferris SH et al (2004) Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol 61:59–66

    Article  PubMed  Google Scholar 

  • Higuchi M, Iwata N, Matsuba Y et al (2005) 19F and 1H MRI detection of amyloid beta plaques in vivo. Nat Neurosci 8(4):527–533

    Article  PubMed  CAS  Google Scholar 

  • Hintersteiner M, Enz A, Frey P et al (2005) In vivo detection of amyloid-beta deposits by near-infrared imaging using an oxazine-derivative probe. Nat Biotechnol 23(5):577–583

    Article  PubMed  CAS  Google Scholar 

  • Hsiao K, Chapman P, Nilsen S et al (1996) Correlative memory deficits, abeta elevation, and amyloid plaques in transgenic mice. Science 274(5284):99–103

    Article  PubMed  CAS  Google Scholar 

  • Ishizawa T, Sahara N, Ishiguro K et al (2003) Co-localization of glycogen synthase kinase-3 with neurofibrillary tangles and granulovacuolar degeneration in transgenic mice. Am J Pathol 163(3):1057–1067

    Article  PubMed  CAS  Google Scholar 

  • Jack CR Jr, Petersen RC, Xu YC et al (1997) Medial temporal atrophy on MRI in normal aging and very mild Alzheimer’s disease. Neurology 49:786–794

    PubMed  Google Scholar 

  • Jack CR Jr, Petersen RC, Xu YC et al (1998) Rate of medial temporal lobe atrophy in typical aging and Alzheimer’s disease. Neurology 51:993–999

    PubMed  Google Scholar 

  • Jack CR Jr, Slomkowski M, Gracon S et al (2003) MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD. Neurology 60(2):253–260

    PubMed  Google Scholar 

  • Jack CR Jr, Shiung MM, Gunter JL et al (2004a) Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology 62(4):591–600

    PubMed  Google Scholar 

  • Jack CR Jr, Garwood M, Wengenack TM et al (2004b) In vivo visualization of Alzheimer’s amyloid plaques by magnetic resonance imaging in transgenic mice without a contrast agent. Magn Reson Med 52(6):1263–1271

    Article  PubMed  Google Scholar 

  • Jack CR Jr, Bernstein MA, Fox NC et al (2008a) The Alzheimer’s disease neuroimaging initiative (ADNI): MRI methods. J Magn Reson Imaging 27(4):685–691

    Article  PubMed  Google Scholar 

  • Jack CR Jr, Lowe VJ, Senjem ML et al (2008b) 11C PiB and structural MRI provide complementary information in imaging of Alzheimer’s disease and amnestic mild cognitive impairment. Brain 131(3):665–680

    Article  PubMed  Google Scholar 

  • Jensen J, Willeit M, Zipursky RB et al (2008) The formation of abnormal associations in schizophrenia: neural and behavioral evidence. Neuropsychopharmacology 33(3):473–479

    Article  PubMed  Google Scholar 

  • Johnson KA, Albert MS (2000) Perfusion abnormalities in prodromal AD. Neurobiol Aging 21(2):289–292

    Article  PubMed  CAS  Google Scholar 

  • Juckel G, Schlagenhauf F, Koslowski M et al (2006) Dysfunction of ventral striatal reward prediction in schizophrenia. Neuroimage 29(2):409–416

    Article  PubMed  Google Scholar 

  • Klunk WE, Engler H, Nordberg A et al (2003) Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol 55(3):306–319

    Article  Google Scholar 

  • Krishnan KRR, Charles HC, Doraiswamy PM et al (2003) Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer’s disease. Am J Psychiatry 160:2003–2011

    Article  PubMed  Google Scholar 

  • Krystal JH, D’Souza DC, Mathalon D et al (2003) NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology 169(3–4):215–233

    Article  PubMed  CAS  Google Scholar 

  • Lahti AC, Weiler MA, Tamara Michaelidis BA et al (2001) Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 25(4):455–467

    Article  PubMed  CAS  Google Scholar 

  • Large CH (2007) Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs? J Psychopharmacol 21(3):283–301

    Article  PubMed  CAS  Google Scholar 

  • Lewis J, McGowan E, Rockwood J et al (2000) Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet 25:402–405

    Article  PubMed  CAS  Google Scholar 

  • Le Pen G, Gaudet L, Mortas P et al (2002) Deficits in reward sensitivity in a neurodevelopmental rat model of schizophrenia. Psychopharmacology 161(4):434–441

    Article  PubMed  Google Scholar 

  • Lipska BK, Weinberger DR (2000) To model a psychiatric disorder in animals: schizophrenia as a reality test. Neuropsychopharmacology 23(3):223–239

    Article  PubMed  CAS  Google Scholar 

  • Littlewood CL, Jones N, O’Neill MJ et al (2006) Mapping the central effects of ketamine in the rat using pharmacological MRI. Psychopharmacology 186(1):64–81

    Article  PubMed  CAS  Google Scholar 

  • Main website of the Alzheimer’s Disease Neuroimaging Initiative. accessed May 2008 http://www.adni-info.org

  • Miller BL, Moats RA, Shonk T et al (1993) Alzheimer disease: depiction of increased cerebral myo-inositol with proton MR spectroscopy. Radiology 187(2):433–437

    PubMed  CAS  Google Scholar 

  • Mueggler T, Baumann D, Rausch M et al (2003) Age-dependent impairment of somatosensory response in the amyloid precursor protein 23 transgenic mouse model of Alzheimer’s disease. J Neurosci 23(23):8231–8236

    PubMed  CAS  Google Scholar 

  • Nordquist RE, Risterucci C, Moreau JL et al (2008) Effects of aripiprazole/OPC-14597 on motor activity, pharmacological models of psychosis, and brain activity in rats. Neuropharmacology 54(2):405–416

    Article  PubMed  CAS  Google Scholar 

  • Olbrich HM, Valerius G, Rüsch N et al (2008) Frontolimbic glutamate alterations in first episode schizophrenia: evidence from a magnetic resonance spectroscopy study. World J Biol Psychiatry 9(1):59–63

    Article  PubMed  Google Scholar 

  • Poduslo JF, Wengenack TM, Curran GL et al (2002) Molecular targeting of Alzheimer’s amyloid plaques for contrast-enhanced magnetic resonance imaging. Neurobiol Dis 11(2): 315–329

    Article  PubMed  CAS  Google Scholar 

  • Redwine JM, Kosofsky B, Jacobs RE et al (2003) Dentate gyrus volume is reduced before onset of plaque formation in PDAPP mice: a magnetic resonance microscopy and stereologic analysis. Proc Natl Acad Sci USA 100(3):1381–1386

    Article  PubMed  CAS  Google Scholar 

  • Richards JG, Higgins GA, Ouagazzal AM et al (2003) PS2APP transgenic mice, coexpressing hPS2mut and hAPPswe, show age-related cognitive deficits associated with discrete brain amyloid deposition and inflammation. J Neurosci 23(26):8989–9003

    PubMed  CAS  Google Scholar 

  • Risterucci C, Jeanneau K, Schöppenthau S et al (2005) Functional magnetic resonance imaging reveals similar brain activity changes in two different animal models of schizophrenia. Psychopharmacology 180(4):724–734

    Article  PubMed  CAS  Google Scholar 

  • Rowland LM, Bustillo JR, Mullins PG et al (2005) Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study. Am J Psychiatry 162(2):394–396

    Article  PubMed  Google Scholar 

  • Scahill R, Frost C, Fox NC et al (2003) A longitudinal study of brain volume changes in normal aging using serial registered magnetic resonance imaging. Arch Neurol 60(7):989–994

    Article  PubMed  Google Scholar 

  • Seal ML, Yücel M, Fornito A et al (2008) Abnormal white matter microstructure in schizophrenia: A voxelwise analysis of axial and radial diffusivity. Schizophr Res 101(1–3):106–110

    Article  PubMed  Google Scholar 

  • Shonk TK, Moats RA, Gifford P et al (1995) Probable Alzheimer disease: diagnosis with proton MR spectroscopy. Radiology 195(1):65–72

    PubMed  CAS  Google Scholar 

  • Szulc A, Galinska B, Tarasow E et al (2005) The effect of risperidone on metabolite measures in the frontal lobe, temporal lobe, and thalamus in schizophrenic patients. A proton magnetic resonance spectroscopy (1H MRS). Pharmacopsychiatry 38(5):214–219

    Article  PubMed  CAS  Google Scholar 

  • Tamminga CA, Thaker GK, Buchanan R et al (1992) Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome. Arch Gen Psychiatry 49(7):522–530

    PubMed  CAS  Google Scholar 

  • Taylor SF, Welsh RC, Chen AC et al (2007) Medial frontal hyperactivity in reality distortion. Biol Psychiatry 61(10):1171–1178

    Article  PubMed  Google Scholar 

  • Umbricht D, Schmid L, Koller R et al (2000) Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia. Arch Gen Psychiatry 57(12):1139–1147

    Article  PubMed  CAS  Google Scholar 

  • Van Broeck B, Vanhoutte G, Pirici D et al (2008) Intraneuronal amyloid beta and reduced brain volume in a novel APP T714I mouse model for Alzheimer’s disease. Neurobiol Aging 29(2):241–252

    Article  PubMed  Google Scholar 

  • Vanhoutte G, Dewachter I, Borghgraef P et al (2005) Noninvasive in vivo MRI detection of neuritic plaques associated with iron in APP(V717I) transgenic mice, a model for Alzheimer’s disease. Magn Reson Med 53(3):607–613

    Article  PubMed  CAS  Google Scholar 

  • von Kienlin M, Künnecke B, Metzger F et al (2005) Altered metabolic profile in the frontal cortex of PS2APP transgenic mice, monitored throughout their life span. Neurobiol Dis 18(1):32–39

    Article  Google Scholar 

  • Wadghiri YZ, Sigurdsson EM, Sadowski M et al (2003) Detection of Alzheimer’s amyloid in transgenic mice using magnetic resonance microimaging. Magn Reson Med 50(2):293–302

    Article  PubMed  CAS  Google Scholar 

  • Weidensteiner C, Metzger F, Bruns A et al (2009) Cortical hypoperfusion in the B6.PS2APP mouse model for Alzheimer’s disease: Comprehensive phenotyping of vascular and tissular parameters by MRI. Magn Reson Med 62(1):35–45

    Google Scholar 

  • Weiss C, Venkatasubramanian PN, Aguado AS et al (2002) Impaired eyeblink conditioning and decreased hippocampal volume in PDAPP V717F mice. Neurobiol Dis 11(3):425–433

    Article  PubMed  CAS  Google Scholar 

  • Weiss AP, Goff D, Schacter DL et al (2006) Fronto-hippocampal function during temporal context monitoring in schizophrenia. Biol Psychiatry 60(11):1268–1277

    Article  PubMed  Google Scholar 

  • Yoon JH, Minzenberg MJ, Ursu S et al (2008) Association of dorsolateral prefrontal cortex dysfunction with disrupted coordinated brain activity in schizophrenia: relationship with impaired cognition, behavioral disorganization, and global function. Am J Psychiatry 165:1006–1014

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neuroscience, F. Hoffmann-La Roche AG, Basel, Switzerland

    Markus von Kienlin

Authors
  1. Markus von Kienlin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Céline Risterucci
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Markus von Kienlin .

Editor information

Editors and Affiliations

  1. Mill Street 115, Belmont, 02478, U.S.A.

    David Borsook

  2. Mill Street 115, Belmont, 02478, U.S.A.

    Lino R. Beccera

  3. Dept. Psychiatry, Addenbrooke's Hospital, Hills Road, Cambridge, CB2 2QQ, United Kingdom

    Edward Bullmore

  4. Sumneytown Pike , West Point, 19486, U.S.A.

    Richard J. Hargreaves

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

von Kienlin, M., Risterucci, C. (2010). Translational MRI in CNS Drug Discovery. In: Borsook, D., Beccera, L., Bullmore, E., Hargreaves, R. (eds) Imaging in CNS Drug Discovery and Development. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-0134-7_14

Download citation

Publish with us

Policies and ethics

Search

Navigation